StreetInsider.com News Articles

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Fri, 19 Jun 2026 16:30:00 -0400

NOVATO, Calif., June 19, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 44,409 restricted stock units of the company’s common stock to 15 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of June 16, 2026, as an inducement material to the new employees entering into employment with Ultragenyx in accordance

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Fri, 19 Jun 2026 16:30:00 -0400

Form 4 Ultragenyx Pharmaceutica For: Jun 15 Filed by: Sanders Corazon (Corsee) D.

Mon, 15 Jun 2026 18:51:00 -0400

si-local-file:///var/storage/secattach/20260615/26648953.html

Form 4 Ultragenyx Pharmaceutica For: Jun 15 Filed by: Sanders Corazon (Corsee) D.

Mon, 15 Jun 2026 18:51:00 -0400

si-local-file:///var/storage/secattach/20260615/26648953.html

Form 4 Ultragenyx Pharmaceutica For: Jun 15 Filed by: Parschauer Karah Herdman

Mon, 15 Jun 2026 18:46:00 -0400

si-local-file:///var/storage/secattach/20260615/26648943.html

Form 4 Ultragenyx Pharmaceutica For: Jun 15 Filed by: Parschauer Karah Herdman

Mon, 15 Jun 2026 18:46:00 -0400

si-local-file:///var/storage/secattach/20260615/26648943.html

Form 144 Ultragenyx Pharmaceutica Filed by: Parschauer Karah Herdman

Mon, 15 Jun 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260615/26648195.html

Form 144 Ultragenyx Pharmaceutica Filed by: Parschauer Karah Herdman

Mon, 15 Jun 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260615/26648195.html

Form 144 Ultragenyx Pharmaceutica Filed by: Sanders Corazon (Corsee) D.

Mon, 15 Jun 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260615/26647474.html

Form 144 Ultragenyx Pharmaceutica Filed by: Sanders Corazon (Corsee) D.

Mon, 15 Jun 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260615/26647474.html

Form S-8 Ultragenyx Pharmaceutica

Fri, 12 Jun 2026 13:40:00 -0400

si-local-file:///var/storage/secattach/20260612/26639965.html

Form S-8 Ultragenyx Pharmaceutica

Fri, 12 Jun 2026 13:40:00 -0400

si-local-file:///var/storage/secattach/20260612/26639965.html

Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference

Wed, 03 Jun 2026 16:30:00 -0400

NOVATO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil Kakkis, M.D., Ph.D., the company's president and chief executive officer will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026, at 4:00 PM ET.

The live and archived webcast of the panel will be accessible from the company’s website at https://ir.ultragenyx.com/events-presentations.

About Ultragenyx Pharmaceutical Inc.

Ultragenyx is a biopharmaceutical

Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference

Wed, 03 Jun 2026 16:30:00 -0400

The live and archived webcast of the panel will be accessible from the company’s website at https://ir.ultragenyx.com/events-presentations.

About Ultragenyx Pharmaceutical Inc.

Ultragenyx is a biopharmaceutical

Form 4 Ultragenyx Pharmaceutica For: Jun 01 Filed by: Horn Howard

Mon, 01 Jun 2026 19:12:00 -0400

si-local-file:///var/storage/secattach/20260601/26585547.html

Form 4 Ultragenyx Pharmaceutica For: Jun 01 Filed by: Horn Howard

Mon, 01 Jun 2026 19:12:00 -0400

si-local-file:///var/storage/secattach/20260601/26585547.html

Form 144 Ultragenyx Pharmaceutica Filed by: Horn Howard

Mon, 01 Jun 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260601/26583605.html

Form 144 Ultragenyx Pharmaceutica Filed by: Horn Howard

Mon, 01 Jun 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260601/26583605.html

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Fri, 22 May 2026 16:30:00 -0400

NOVATO, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 17,567 restricted stock units of the company’s common stock to 11 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of May 16, 2026, as an inducement material to the new employees entering into employment with Ultragenyx in accordance

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Fri, 22 May 2026 16:30:00 -0400

Ultragenyx Pharma (RARE) PT Raised to $96 at Cantor Fitzgerald

Thu, 21 May 2026 06:36:39 -0400

Cantor Fitzgerald analyst Kristen Kluska raised the price target on Ultragenyx Pharma (NASDAQ: RARE) to $96.00 (from $84.00) while maintaining a Overweight rating.

The analyst comments "When we originally launched coverage of RARE, the majority of our thesis was on setrusumab for osteogenesis imperfecta, a call we recognize we were wrong on. ● Our original thesis was very conservative on GTX-102 for Angelman syndrome. ● Over the last two months, we have spent significant time diving deeper into this program with our deep dive (link), and virtual Angelman syndrome week: Day 1 (link), Day 2 (link), Day 3 (link), Day 4

Ultragenyx Pharma (RARE) PT Raised to $96 at Cantor Fitzgerald

Thu, 21 May 2026 06:36:39 -0400

Cantor Fitzgerald analyst Kristen Kluska raised the price target on Ultragenyx Pharma (NASDAQ: RARE) to $96.00 (from $84.00) while maintaining a Overweight rating.

Ultragenyx Pharma (RARE) PT Lowered to $72 at JPMorgan

Wed, 20 May 2026 07:37:21 -0400

JPMorgan analyst Anupam Rama lowered the price target on Ultragenyx Pharma (NASDAQ: RARE) to $72.00 (from $74.00) while maintaining a Overweight rating.

Form 4 Ultragenyx Pharmaceutica For: May 14 Filed by: Fust Matthew K

Mon, 18 May 2026 18:51:00 -0400

si-local-file:///var/storage/secattach/20260518/26515552.html

Form 4 Ultragenyx Pharmaceutica For: May 14 Filed by: Fust Matthew K

Mon, 18 May 2026 18:51:00 -0400

si-local-file:///var/storage/secattach/20260518/26515552.html